RIGEL PHARMACEUTICALS INC (RIGL)
US7665597024 - Common Stock
Overall RIGL gets a fundamental rating of 5 out of 10. We evaluated RIGL against 564 industry peers in the Biotechnology industry. RIGL has a medium profitability rating, but doesn't score so well on its financial health evaluation. RIGL is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year RIGL was profitable.
RIGL had a positive operating cash flow in the past year.
In the past 5 years RIGL always reported negative net income.
In the past 5 years RIGL reported 4 times negative operating cash flow.
1.2 Ratios
RIGL has a Return On Assets of 2.78%. This is amongst the best in the industry. RIGL outperforms 93.72% of its industry peers.
With an excellent Return On Invested Capital value of 8.82%, RIGL belongs to the best of the industry, outperforming 95.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.78% | ||
| ROE | N/A | ||
| ROIC | 8.82% |
ROA(3y)-25.25%
ROA(5y)-29.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of RIGL (2.46%) is better than 93.72% of its industry peers.
The Operating Margin of RIGL (6.03%) is better than 94.61% of its industry peers.
RIGL's Gross Margin of 89.43% is amongst the best of the industry. RIGL outperforms 92.64% of its industry peers.
RIGL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.03% | ||
| PM (TTM) | 2.46% | ||
| GM | 89.43% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y-1.11%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for RIGL has been reduced compared to 1 year ago.
The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
Compared to 1 year ago, RIGL has a worse debt to assets ratio.
2.2 Solvency
RIGL has an Altman-Z score of -11.11. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RIGL (-11.11) is worse than 77.02% of its industry peers.
RIGL has a debt to FCF ratio of 5.77. This is a neutral value as RIGL would need 5.77 years to pay back of all of its debts.
RIGL has a better Debt to FCF ratio (5.77) than 93.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.77 | ||
| Altman-Z | -11.11 |
ROIC/WACC0.8
WACC11.09%
2.3 Liquidity
RIGL has a Current Ratio of 1.96. This is a normal value and indicates that RIGL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of RIGL (1.96) is worse than 76.12% of its industry peers.
A Quick Ratio of 1.87 indicates that RIGL should not have too much problems paying its short term obligations.
RIGL has a worse Quick ratio (1.87) than 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 110.00% over the past year.
RIGL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.97%.
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.30% yearly.
EPS 1Y (TTM)110%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)18.97%
Revenue growth 3Y2.48%
Revenue growth 5Y21.3%
Sales Q2Q%96.58%
3.2 Future
RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.33% yearly.
The Revenue is expected to grow by 18.94% on average over the next years. This is quite good.
EPS Next Y119.54%
EPS Next 2Y63.23%
EPS Next 3Y48.91%
EPS Next 5Y26.33%
Revenue Next Year47.4%
Revenue Next 2Y29.87%
Revenue Next 3Y25.38%
Revenue Next 5Y18.94%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 124.14, which means the current valuation is very expensive for RIGL.
92.46% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
RIGL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
RIGL is valuated rather expensively with a Price/Forward Earnings ratio of 17.44.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 95.15% of the companies listed in the same industry.
RIGL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.14 | ||
| Fwd PE | 17.44 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 94.79% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 95.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.57 | ||
| EV/EBITDA | 25.88 |
4.3 Compensation for Growth
RIGL's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
RIGL's earnings are expected to grow with 48.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.04
PEG (5Y)N/A
EPS Next 2Y63.23%
EPS Next 3Y48.91%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RIGEL PHARMACEUTICALS INC
NASDAQ:RIGL (1/3/2025, 8:00:01 PM)
After market: 17.38 0 (0%)17.38
+0.06 (+0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners59.42%
Inst Owner Change144.31%
Ins Owners2.04%
Ins Owner Change0%
Market Cap306.24M
Analysts76.67
Price Target31.96 (83.89%)
Short Float %3.69%
Short Ratio2.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)578.2%
Min EPS beat(2)79.86%
Max EPS beat(2)1076.54%
EPS beat(4)3
Avg EPS beat(4)296.59%
Min EPS beat(4)-70.03%
Max EPS beat(4)1076.54%
EPS beat(8)7
Avg EPS beat(8)177.87%
EPS beat(12)10
Avg EPS beat(12)122.06%
EPS beat(16)13
Avg EPS beat(16)365.55%
Revenue beat(2)2
Avg Revenue beat(2)18.7%
Min Revenue beat(2)8.08%
Max Revenue beat(2)29.32%
Revenue beat(4)3
Avg Revenue beat(4)8.21%
Min Revenue beat(4)-7.45%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)15.34%
Revenue beat(12)8
Avg Revenue beat(12)10.7%
Revenue beat(16)10
Avg Revenue beat(16)18.76%
PT rev (1m)7.43%
PT rev (3m)20.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1921.42%
EPS NY rev (1m)0%
EPS NY rev (3m)182.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 124.14 | ||
| Fwd PE | 17.44 | ||
| P/S | 1.94 | ||
| P/FCF | 29.57 | ||
| P/OCF | 28.55 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.88 |
EPS(TTM)0.14
EY0.81%
EPS(NY)1
Fwd EY5.73%
FCF(TTM)0.59
FCFY3.38%
OCF(TTM)0.61
OCFY3.5%
SpS8.94
BVpS-0.83
TBVpS-2.4
PEG (NY)1.04
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.78% | ||
| ROE | N/A | ||
| ROCE | 11.17% | ||
| ROIC | 8.82% | ||
| ROICexc | 31.29% | ||
| ROICexgc | N/A | ||
| OM | 6.03% | ||
| PM (TTM) | 2.46% | ||
| GM | 89.43% | ||
| FCFM | 6.58% |
ROA(3y)-25.25%
ROA(5y)-29.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5Y-1.11%
F-Score5
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.77 | ||
| Debt/EBITDA | 5.24 | ||
| Cap/Depr | 19.35% | ||
| Cap/Sales | 0.23% | ||
| Interest Coverage | 1.36 | ||
| Cash Conversion | 93.96% | ||
| Profit Quality | 266.81% | ||
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.87 | ||
| Altman-Z | -11.11 |
F-Score5
WACC11.09%
ROIC/WACC0.8
Cap/Depr(3y)436.98%
Cap/Depr(5y)340.62%
Cap/Sales(3y)4.54%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)110%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y119.54%
EPS Next 2Y63.23%
EPS Next 3Y48.91%
EPS Next 5Y26.33%
Revenue 1Y (TTM)18.97%
Revenue growth 3Y2.48%
Revenue growth 5Y21.3%
Sales Q2Q%96.58%
Revenue Next Year47.4%
Revenue Next 2Y29.87%
Revenue Next 3Y25.38%
Revenue Next 5Y18.94%
EBIT growth 1Y149.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year151.39%
EBIT Next 3Y62.1%
EBIT Next 5YN/A
FCF growth 1Y114.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y115.12%
OCF growth 3YN/A
OCF growth 5YN/A